Dr. Guowen Yin 尹国文
Chief Physician
Department of Interventional Therapy, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional diagnosis and treatment of liver, pancreatic, biliary, esophageal, gastric, lung, and pelvic tumors, as well as various fistulas.
Dr. Yin is Chief Physician and Department Director at Jiangsu Cancer Hospital. The doctor specializes in interventional therapies, including embolization chemotherapy, radiofrequency ablation, gene therapy, targeted and biological therapy, and radioactive internal irradiation. Procedures include stent placement in the esophagus, trachea, bile duct, intestine, and blood vessels, as well as feeding tube insertion. Dr. Yin has received multiple awards for new technology introduction from the Provincial Health Department.
Name order: in Chinese the family name comes first (Yin Guowen). Papers usually list the name as Guowen Yin or Yin G.
Selected publications
35 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Med, 2026 (senior author): Efficacy of Hepatic Artery Infusion Chemotherapy Combined With Regorafenib and Sintilimab Versus Regorafenib Alone in MSS/pMMR Colorectal Cancer Liver Metastases After Second-Line Treatment Failure. PubMed 42043896
- Discov Oncol, 2025 (senior author): Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series. PubMed 40779236
- Discov Oncol, 2025 (senior author): Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma. PubMed 40374824
- Discov Oncol, 2025 (senior author): Comparison of liver injury and inflammatory response following conventional and drug-eluting bead transcatheter chemoembolization in hepatocellular carcinoma. PubMed 40208482
- Drugs Real World Outcomes, 2025 (senior author): Comparative Efficacy of Lenvatinib Plus Immunotherapy and Regorafenib Plus Immunotherapy After Lenvatinib Failure for Advanced Hepatocellular Carcinoma: A Retrospective Study. PubMed 39833610
- Invest New Drugs, 2025 (senior author): Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study. PubMed 39762642
- Biomedicines, 2024 (senior author): Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study. PubMed 39335637
- J Gastroenterol Hepatol, 2024 (senior author): Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE. PubMed 38240156
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion